期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

基于SCORE函数估算HLA-A*0201限制性CTL表位亲和性 被引量：1

Estimation of the affinity of HLA-A*0201 restricted CTL epitope based on SCORE function
在线阅读 下载PDF
导出
摘要 目的建立HLA-A*0201限制性CTL表位亲和性的定量预测方法。方法基于SCORE打分函数,运用定量构效关系的理论和方法研究了HLA-A*0201限制性CTL表位九肽结构与亲和性间的定量关系,并建立了SCORE得分与亲和性的定量关系模型,并用外部样本(5个HLA-A*0201限制性CTL表位九肽)作为预测集用于检验模型的预测能力。结果基于SCORE打分函数建立的定量模型具有较好的相关性(r=0.9165,RMS=0.38)和对外部样本的预测能力(rpred=0.9847,RMS=0.135)。结论基于SCORE打分函数,运用定量构效关系研究的理论和方法建立了HLA-A*0201限制性CTL表位亲和性的定量预测方法,为实验鉴定高亲和性HLA-A*0201限制性CTL表位提供了理论依据。 Objective To construct a new method for predicting the affinity of the HLA-A*0201 restricted CTL epitope in quantitative way. Methods The quantitative relationship, between structure score and the affinity of the HLA-A*0201 restricted CTL epitopes, was stu- died based on the SCORE function by using the theory and method of QSAR. A test set including 5 HLA-A*0201 restricted CTL epitopes was used to validate the quantitative model. Results The quantitative model has good correlation ( r = 0.9165, RMS = 0.38), and good predic- tability for outside samples ( r _ pred = 0.9847, RMS = 0.135). Conclusion A new method for predicting the affinity of the HLA-A*0201 restricted CTL epitope is constructed based on the SCORE function by using QSAR method, which provides a theory base for identifying the CTL eptiope by experimental methods and designing a new therapeutic vaccine.
作者 朱波 林治华 陈正堂 吴玉章
机构地区 第三军医大学新桥医院全军肿瘤中心 重庆工学院生物工程学院 第三军医大学基础部全军免疫学研究所
出处 《免疫学杂志》 CAS CSCD 北大核心 2005年第3期177-181,共5页 Immunological Journal
基金 国家自然科学基金(30490240 30471579 30300150) 国家"973"计划(2001CB510001)资助项目
关键词 SCORE函数 HLA-A＊0201 CTL表位 亲和性 SCORE function HLA-A*0201 CTL epitope Affinity
分类号 R730.3 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities [J]. J Virol, 2004, 78 (5): 2 187 - 2 200.
  • 2Takedatsu H, Shichijo S, Katagiri K, et al. Identification of peptide vaccine candidates sharing among HLA-A3^+,- A11^+ , - A31^+ , and - A33^+ cancer patients [J]. Clin Cancer Res, 2004, 10 (3):1 112- 1 120.
  • 3Webb AI, Dunstone MA, Chen W, et al. Functional and tructural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue [J]. J Biol Chem, 2004, 279 (22): 23 438 - 23 446.
  • 4Yamaguchi H, Tanaka F, Ohta M, et al. Identification of HLA-A24-restricted CTL epitope from cancer- testis antigen,NY-ESO-1, and induction of a specific antitumor immune response [J]. Clin Cancer Res, 2004, 10 (3): 890-896.
  • 5Hebart H, Rauser G, Stevanovic S, et al. A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic stem cell transplantation [J]. Exp Hematol, 2003, 31 (10):966 - 973.
  • 6De Groot AS, Jesdale B, Martin W, et al. Mapping crossclade HIV-1 vaccine epitopes using a bioinformatics approach [J]. Vaccine, 2003, 21(27/30):4 486-4 504.
  • 7Wang RX, Liu L, Lai LH, et al. SCORE: a new empirical method for estimating the binding affinity of a protein-ligand complex [J]. J Mol Model, 1998, 4 (12), 379-394.
  • 8Nicklaus MC, Wang S, Driscoll JS, et al. Conformational changes of small molecules binding to proteins [J]. Bioorg Med Chem, 1995, 3 (4): 411- 428.
  • 9Rongcun Y, Salazar Onfray F, Charo J, et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas [J]. J Immunol, 1999, 163(2): 1 037 - 1 044.
  • 10Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affnity and immunogenicity of potential cytotoxic T cell epitopes [J]. J Immunol, 1994, 153 (12):5 586 - 5 592.

二级参考文献56

  • 1[1]Feller A J, Duan Z, Penson R, et al. TRAG-3, a novel cancer/testis antigen, is overexpressed in the majority of melanoma cell lines and malignant melanoma [J]. Anticancer Res, 2000, 20(6B): 4 147-4 151.
  • 2[2]Chen Z, Zhu B, Wu Y. Expression of TRAG-3 antigen in non-small-cell lung carcinomas [J]. Lung Cancer, 2002,38(1): 101-102.
  • 3[5]Rosenberg SA. Progress in human tumor immunology and immunotherapy [J]. Nature, 2001, 411(6 835): 380-384.
  • 4[7]Schirle M, Weinschenk T, Stevanovic S. Combining computer algorithms with experimental approaches permits the rapid and accurate identificaton of T cell epitopes from defined antigens [J]. J Immunol Methods, 2001, 257(1/2): 1-16.
  • 5[8]Celis E, Fikes J, Wentworth P, et al. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles [J]. Mol Immunol, 1994,31(18): 1 423-1 430.
  • 6[9]van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3 [J]. Eur J Immunol, 1994, 24(12):3 038-3 043.
  • 7[10]Parkhurst MR, Fitzgerald EB, Southwood S, et al. Identification of a shared HLA-A * 0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2) [J]. Cancer Res, 1998,58(21 ): 4 895-4 901.
  • 8Hagmann M.. Science[J], 2000, 290:80-82.
  • 9Mallios R, R, . Bioinformatics[J], 1999, 15(6) : 432-439.
  • 10Odun,si K.. Ganesan T,. Int. Mol. Med. [J], 2001, 8(4): 405-412.

共引文献9

同被引文献9

引证文献1

二级引证文献2

免疫学杂志
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部